We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+117.73%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.51B
AUM Growth
+$863M
Cap. Flow
-$27.8M
Cap. Flow %
-1.11%
Top 10 Hldgs %
46.81%
Holding
87
New
12
Increased
10
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
VIE
Viela Bio, Inc. Common Stock
VIE
+$37.7M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$31.4M
3
ZYME icon
Zymeworks
ZYME
+$25.4M
4
CABA icon
Cabaletta Bio
CABA
+$25.1M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$24.2M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.6M
2
QURE icon
uniQure
QURE
+$27.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$16.1M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.9M
5
ALLK
Allakos
ALLK
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.68B
$32.3M 1.29%
250,000
+28,300
+13% +$2.86M
ZYME icon
27
Zymeworks
ZYME
$1.73B
$31.8M 1.27%
+700,000
New +$25.4M
MYOV
28
DELISTED
Myovant Sciences Ltd.
MYOV
$31M 1.24%
+2,000,000
New +$20.2M
CABA icon
29
Cabaletta Bio
CABA
$442M
$29.6M 1.18%
+2,119,132
New +$25.1M
QURE icon
30
uniQure
QURE
$3.07B
$28.7M 1.14%
400,000
-500,000
-56% -$27.5M
ALLK
31
DELISTED
Allakos
ALLK
$28.6M 1.14%
300,000
-144,100
-32% -$12.7M
EIDX
32
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$28.4M 1.14%
495,692
-44,994
-8% -$2.23M
DCPH
33
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$28M 1.12%
450,000
-338,500
-43% -$16.1M
AMRN
34
Amarin Corp
AMRN
$302M
$27.9M 1.11%
65,000
-1,600
-2% -$608K
BPMC
35
DELISTED
Blueprint Medicines
BPMC
$27.6M 1.1%
345,000
-148,000
-30% -$11.1M
BHVN
36
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$27.2M 1.09%
500,000
-100,000
-17% -$4.95M
IMVTU
37
DELISTED
Immunovant, Inc. Units
IMVTU
$26.5M 1.06%
+1,080,000
New +$23.3M
OMER icon
38
Omeros
OMER
$916M
$21.5M 0.86%
+1,525,000
New +$22.3M
LKFT
39
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$20.9M 0.83%
100,000
-50,000
-33% -$9.24M
STSA
40
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$16.9M 0.67%
858,382
– –
AKRO
41
DELISTED
Akero Therapeutics
AKRO
$16.4M 0.66%
740,621
– –
ARGX icon
42
argenx
ARGX
$54.3B
$16.1M 0.64%
100,000
-28,110
-22% -$3.8M
TWST icon
43
Twist Bioscience
TWST
$7.16B
$14.4M 0.58%
687,149
– –
MRUS
44
DELISTED
Merus
MRUS
$14.1M 0.56%
+1,000,000
New +$16.1M
RARX
45
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$13.9M 0.55%
295,600
– –
KURA icon
46
Kura Oncology
KURA
$817M
$13.8M 0.55%
1,000,000
-231,500
-19% -$3.43M
SRNE
47
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$13.5M 0.54%
+4,000,000
New +$9.54M
INSP icon
48
Inspire Medical Systems
INSP
$1.73B
$12.8M 0.51%
172,300
– –
EIGR
49
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$12.4M 0.5%
27,780
-5,483
-16% -$1.95M
ZLAB icon
50
Zai Lab
ZLAB
$2.07B
$11.5M 0.46%
277,161
– –
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Cormorant Asset Management held 87 positions worth $2.51B, up 53% from $1.64B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q4 2019 filing shows 12 new, 10 increased, 29 reduced and 20 closed positions. Its largest new stake was Viela Bio, Inc. Common Stock: 1,497,500 shares worth $40.7M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier.

  • Cormorant Asset Management's largest Q4 2019 buy was Viela Bio, Inc. Common Stock: 1,497,500 shares worth $40.7M.
  • Cormorant Asset Management added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $31.4M increase.
  • Cormorant Asset Management's biggest Q4 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $30.6M.
  • Cormorant Asset Management fully exited Sage Therapeutics in Q4 2019, selling an estimated $12.4M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $2.51B portfolio in Q4 2019.
  • Cormorant Asset Management opened 12 new positions and closed 20 in Q4 2019.
  • Cormorant Asset Management's portfolio value rose 53% quarter-over-quarter to $2.51B.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.